Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23


24P - TGF-?RI contributes to tamoxifen response in luminal B breast cancer with HER2 negative phenotype


06 Oct 2021




Nataliya Babyshkina


Annals of Oncology (2021) 32 (suppl_6): S1345-S1371. 10.1016/annonc/annonc740


N. Babyshkina1, T. Dronova2, S. Vtorushin3, S. Patalyak3, N. Cherdyntseva3

Author affiliations

  • 1 Tomsk National Research Medical Center, Tomsk/RU
  • 2 Tomsk National Research Medical Center, Russian Academy of Sciences, Cancer Research Institute, 634009 - Tomsk/RU
  • 3 Tomsk National Research Medical Center of the Russian Academy of Sciences, Cancer Research Institute, 634009 - Tomsk/RU

Abstract 24P


TGF-β signaling is highly important in tumor growth and progression, however, the value of TGF-β family proteins as potential resistance-related markers is not fully understood, especially in breast cancer molecular subtypes. The aim of this study was to examine the contribution of TGF-β family proteins to tamoxifen response in luminal breast cancer patients with different HER2 phenotypes.


TGF-β, TGF-βRI, TGF-βRII and ERα mRNA and protein expression levels were quantified using quantitative real-time polymerase chain reaction and immunohistochemistry, respectively, in 60 tissue specimens from breast cancer patients with luminal B HER2 negative and luminal HER2 positive phenotype. Flow cytometry was used to evaluate the co-expression of TGF-βRI and CD24 in breast cancer tissue. Association analysis of progression-free survival (PFS) with selected markers was conducted using Kaplan-Meier plots and log-rank test. Tamoxifen resistance was defined as clinical progression during disease treatment or relapse.


High mRNA expression of ESR1 as well as homogeneous ERα expression in tumor were significantly related to favorable tamoxifen response in luminal B breast cancer patients with HER2-negative phenotype (р = 0.046 and p = 0.011; respectively). Furthermore, these patients with high level of TGF-βR1 expression had a significantly better prognosis than those with low TGF-βR1 expression in the tumor (p = 0.021). Luminal B HER2 negative tumors with TGF-βRI-positive expression tended to be closely associated with the homogeneous ERα expression, although this difference was not significant (p = 0.18). The expression of TGF-βRI was significantly correlated with progression-free survival in luminal B HER2-negative patients (log-rank p = 0.010).


The findings of the present study suggest that TGF-βRI may be used as a potential target for the tamoxifen treatment of luminal B breast cancer patients with HER2-negative phenotype. Further study is required to assess the possible relationship between the TGF-β family proteins and tamoxifen responsiveness in luminal HER2 positive breast cancer.

Legal entity responsible for the study

The authors.


Russian Scientific Foundation, grant #19-75-30016.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.